GMV participates in IMI’s 10th anniversary celebration

GMV presents the Harmony and MOPEAD projects during its participation in IMI’s 10th anniversary celebration

The Innovative Medicine Initiative (IMI) was set up ten years ago to improve the health of European citizens by speeding up the development of and patient access to innovative medicine, especially in areas where there is an unmet social or medical need. IMI is the world's biggest public-private partnership (PPP) in the life sciences. It is made up by the key players involved in healthcare research, including universities, research centers, small and medium-sized enterprises (SMEs), patient organizations, and medicines regulators of the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations).

GMV, as technological leader of two IMI projects, Harmony (blood diseases) and MOPEAD (Alzheimer’s), has taken part in this event, which has presented the result of IMI-driven projects in areas as diverse as cancer, resistance to antimicrobial agents, Alzheimer’s, digital health or Ebola.

Adrián Rodrigo, GMV’s Business solutions - Smart Health Manager, represented the company by talking about the work carried out under the MOPEAD project (Models of Patient Engagement for Alzheimer's disease). This involves a web platform for online identification of citizens at risk of suffering cognitive problems, including Alzheimer’s. Its design combines online marketing strategies and concepts such as usability and advanced analytics. The Citizen Science platform, led by GMV, is designed to allow different population segments to search online for information about concepts related with memory care, healthy lifestyles or Alzheimer’s.

The platform also offers informative content on the disease and explains the purpose of the MOPEAD project, inviting the public to take part. Various online cognitive tests on the platform enable people aged 65 to 85 to assess their risk of suffering from Alzheimer’s.

Furthermore, in order to process the data thus obtained, GMV has also developed an intelligent application that generates high-quality standardized data sources to help decision making in the various strategies to be implemented. These high-quality data sources, fed into the Big Data platform, will throw up results and evidence that will help to document publications, combining and enriching the data, analyzing events and turning the data into evidence.